Cover Image
市場調查報告書

大型製藥公司的合作契約

Global Big Pharma Partnering Terms and Agreements 2010-2016: Deal Trends, Players and Financials

出版商 Current Partnering, a division of Wildwood Ventures Limited 商品編碼 244587
出版日期 內容資訊 英文 1000+ Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
大型製藥公司的合作契約 Global Big Pharma Partnering Terms and Agreements 2010-2016: Deal Trends, Players and Financials
出版日期: 2016年10月05日 內容資訊: 英文 1000+ Pages
簡介

本報告提供全球前50大大型製藥公司的企業簡介和合作契約動向調查分析,合作契約,合作夥伴·交易類型·產業部門·開發現階段·技術類型·各治療領域的合作契約詳細內容,大型經營者的方法法的檢驗等彙整資料,為您概述為以下內容。

摘要整理

第1章 簡介

第2章 前50大大型製藥公司的交易活動

  • 簡介
  • 長期交易
  • 各交易類型
  • 各產品部門
  • 各開發階段
  • 各技術類型
  • 治療各領域
  • 長期的收購與合併

第3章 主要交易:各交易金額

  • 簡介
  • 合作
  • M&A

第4章 大型製藥公司的機會提案

  • 提案的方法
  • 提案的模板
  • 電子郵件發送
  • 合作活動的面談
  • 線上提案格式

第5章 今後的合作活動

第6章 企業簡介

  • 簡介
  • 範圍定義
  • 企業簡介

第7章 資源

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: CP1010
‘Global Big Pharma Partnering Terms and Agreements 2010 to 2016 ’ report provides a detailed understanding and analysis of how and why companies enter Big Pharma partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

This report provides details of the latest Big Pharma agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review Big Pharma deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Big Pharma partnering deals.

The report presents financial deal term values for Big Pharma deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Big Pharma partnering field; both the leading deal values and most active Big Pharma dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 3,000 online deal records of actual Big Pharma deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Big Pharma dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Big Pharma dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Big Pharma deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 most active companies including Pfizer, Sanofi, Abbott, GlaxoSmithKline, Johnson & Johnson and many others, in Big Pharma dealmaking with a brief summary followed by a comprehensive listing of Big Pharma deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of Big Pharma partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Big Pharma partnering deals signed and announced since Jan 2010. The chapter is organized by specific technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Big Pharma partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Big Pharma partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Big Pharma technologies and products.

Key benefits

‘Global Big Pharma Partnering 2010-2016: Deal trends, players, financials and forecasts ’ provides the reader with the following key benefits:

  • In-depth understanding of Big Pharma deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Big Pharma agreements with real life case studies
  • Detailed access to actual Big Pharma contracts entered into by leading biopharma companies
  • Identify most active Big Pharma dealmakers since 2010
  • Insight into terms included in a Big Pharma partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

port scope

‘Global Big Pharma Partnering 2010-2016: Deal trends, players, financials and forecasts ’ is intended to provide the reader with an in-depth understanding and access to Big Pharma trends and structure of deals entered into by leading companies worldwide.

‘Big Pharma Partnering Terms and Agreements ’ includes:

  • Trends in Big Pharma dealmaking in the biopharma industry since 2010
  • Analysis of Big Pharma deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life Big Pharma deals
  • Access to Big Pharma contract documents
  • Leading Big Pharma deals by value since 2010
  • Most active Big Pharma dealmakers since 2010

In ‘Global Big Pharma Partnering 2010-2016: Deal trends, players, financials and forecasts ’, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The ‘Global Big Pharma Partnering 2010-2016: Deal trends, players, financials and forecasts ’ report provides comprehensive access to available deals and contract documents for over 3,000 Big Pharma deals.

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Big Pharma dealmaking

  • 2.1. Introduction
  • 2.2. Big Pharma partnering over the years
  • 2.3. Most active Big Pharma dealmakers
  • 2.4. Big Pharma partnering by deal type
  • 2.5. Big Pharma partnering by therapy area
  • 2.6. Big Pharma partnering by technology type
  • 2.7. Deal terms for Big Pharma partnering
    • 2.7.1. Big Pharma partnering headline values
    • 2.7.2. Big Pharma deal upfront payments
    • 2.7.3. Big Pharma deal milestone payments
    • 2.7.4. Big Pharma royalty rates

Chapter 3 - Leading Big Pharma deals

  • 3.1. Introduction
  • 3.2. Top Big Pharma deals by value

Chapter 4 - Most active Big Pharma dealmakers

  • 4.1. Introduction
  • 4.2. Most active Big Pharma dealmakers
  • 4.3. Most active Big Pharma partnering company profiles
    • Including Pfizer, Sanofi, Abbott, GlaxoSmithKline, Johnson & Johnson and many others

Chapter 5 - Big Pharma contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Big Pharma contracts dealmaking directory

Chapter 6 - Big Pharma dealmaking by technology type

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

Appendix 1 - Big Pharma deals by company A-Z

Appendix 2 - Big Pharma deals by stage of development

Appendix 3 - Big Pharma deals by deal type

Appendix 4 - Big Pharma deals by therapy area

Appendix 5 - Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Big Pharma partnering since 2010
  • Figure 2: Active Big Pharma dealmaking activity- 2010 to 2016
  • Figure 3: Big Pharma partnering by deal type since 2010
  • Figure 4: Big Pharma partnering by disease type since 2010
  • Figure 5: Big Pharma partnering by technology type since 2010
  • Figure 6: Big Pharma deals with a headline value
  • Figure 7: Big Pharma deals with an upfront value
  • Figure 8: Big Pharma deals with a milestone value
  • Figure 9: Big Pharma deals with a royalty rate value
  • Figure 10: Top Big Pharma deals by value since 2010
  • Figure 11: Most active Big Pharma dealmakers 2010 to 2016
  • Figure 12: Online partnering resources
  • Figure 13: Forthcoming partnering events
Back to Top